The advent of DMT in AD is a welcome development but the real-world benefit of these medications for older adults is yet to be determined. For geriatricians, AD significantly contributes to later-life rates of institutionalisation, frailty, falls, continence issues and other geriatric syndromes associated with diminished quality of life. We must consider the potential effect of any potential DMT on these important outcomes and advocate for their inclusion in clinical trials alongside traditional gold-standard dementia severity assessments. As geriatricians, there must be a delicate balance between advocating for timely access to any potential DMT which may benefit older adults with AD and advocacy for continued and enhanced supportive care pathways for older adults with more advanced AD or more significant levels of frailty who may not be eligible for new DMT. Whilst the needle has indeed been moved by the potential emergence of DMT, we must ensure that older adults with more severe AD are not left behind and cautiously evaluate the real-world clinical impact of potential DMT on gerontologically-focussed outcomes which are important to older adults, their caregivers and clinicians alike.

Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia / Dyer, Adam H.; Dolphin, Helena; Shenkin, Susan D.; Welsh, Tomas; Soysal, Pinar; Roitto, Hanna-Maria; Religa, Dorota; Kennelly, Sean P.; null, null; Soylemez, Burcu Akpinar; Alves, Mariana; Atbas, Cansu; Balci, Cafer; Bellelli, Giuseppe; Blanc, Frederic; Cavusoglu, Cagatay; Chen, Yaohua; Cherdak, Maria; Coin, Alessandra; Cozza, Maria Giovanna; Dangiolo, Mariana; Dani, Melanie; Dogu, Burcu Balam; Du, Jamin; Eleftheriades, Christina; Frisardi, Vincenza; Froelich, Lutz; Guney, Seda; Harwood, Rowan Harold; Huang, Allen; Isaev, Ruslan; Okudur, Saadet Koc; Leroy, Victoire; Luis, Maria Margarida; Macijauskiene, Jurate; Milosavljevik, Pavlinka; Mkhitaryan, Elen; Molnar, Frank; Mossello, Enrico; Passmore, Peter; Peeters, Geeske; Pozzi, Christian; Quinn, Terence; Rahman, Shibley; Rosendahl, Erik; Roy, Amrita; Sizoo, Eefje; Smith, Lee; Tannou, Thomas; Tatzer, Verena; Timmons, Suzanne; Tournoy, Jos; Valimaki, Tarja; Velevska, Maja; Vardy, Emma; Veronese, Nicola; Zamfir, Mihai. - In: EUROPEAN GERIATRIC MEDICINE. - ISSN 1878-7657. - STAMPA. - 14:(2023), pp. 919-923. [10.1007/s41999-023-00846-2]

Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia

Mossello, Enrico;
2023

Abstract

The advent of DMT in AD is a welcome development but the real-world benefit of these medications for older adults is yet to be determined. For geriatricians, AD significantly contributes to later-life rates of institutionalisation, frailty, falls, continence issues and other geriatric syndromes associated with diminished quality of life. We must consider the potential effect of any potential DMT on these important outcomes and advocate for their inclusion in clinical trials alongside traditional gold-standard dementia severity assessments. As geriatricians, there must be a delicate balance between advocating for timely access to any potential DMT which may benefit older adults with AD and advocacy for continued and enhanced supportive care pathways for older adults with more advanced AD or more significant levels of frailty who may not be eligible for new DMT. Whilst the needle has indeed been moved by the potential emergence of DMT, we must ensure that older adults with more severe AD are not left behind and cautiously evaluate the real-world clinical impact of potential DMT on gerontologically-focussed outcomes which are important to older adults, their caregivers and clinicians alike.
2023
14
919
923
Goal 3: Good health and well-being
Dyer, Adam H.; Dolphin, Helena; Shenkin, Susan D.; Welsh, Tomas; Soysal, Pinar; Roitto, Hanna-Maria; Religa, Dorota; Kennelly, Sean P.; null, null; So...espandi
File in questo prodotto:
File Dimensione Formato  
s41999-023-00846-2.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 344.44 kB
Formato Adobe PDF
344.44 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1391603
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact